HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.
Evommune, Inc. is a biotechnology company based in Los Altos, California, focused on developing and manufacturing tissue-based medicines for inflammatory diseases. Established in 2020, the company aims to improve the quality of life for patients by addressing the underlying causes of these conditions. Evommune employs a proprietary tissue-based platform designed to accelerate the discovery of novel therapies while predicting their clinical success. This innovative approach enhances the capabilities of health professionals in the fields of immunology and dermatology, allowing for the development of treatments that effectively target symptoms and hinder disease progression.
Operator of a biopharmaceutical company intended to discover and develop therapies that slow or stop the progression of neurodegenerative diseases. The company engages in identifying new medicines to preserve cognition and other brain functions and enhance resilience to neurodegenerative diseases including Alzheimer's, Frontotemporal Dementia, and Parkinson's, enabling people suffering from neurodegenerative diseases to access suitable therapeutics for fast recovery.
New Amsterdam Pharma B.V. is a clinical-stage biopharmaceutical company based in Naarden, the Netherlands, focused on researching and developing innovative therapies for cardio-metabolic diseases. Founded in 2019, the company is dedicated to improving patient care for those with metabolic disorders, particularly where existing treatments are inadequate or poorly tolerated. Its lead product, obicetrapib, is a next-generation oral CETP inhibitor designed to provide a preferred LDL cholesterol-lowering option for patients who experience statin intolerance or for those with Arteriosclerotic Cardiovascular Disease and Familial Hypercholesterolemia who are on maximally tolerated statin therapy.
Lumeon Ltd. is a digital health company specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and headquartered in London, the company offers a cloud-based platform known as the Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. Lumeon's services encompass business analysis, project management, data migration, training, and ongoing support. By focusing on the entire care pathway, Lumeon aids healthcare providers in optimizing clinical and administrative workflows, automating tasks, and achieving measurable healthcare outcomes. The company serves a diverse range of clients, including some of Europe's leading healthcare organizations. Lumeon was previously known as Qinec Ltd. before rebranding in July 2016.
ImCyse SA is a clinical-stage biotechnology company based in Liège, Belgium, founded in 2010. The company focuses on developing active immunotherapeutics aimed at treating and preventing severe chronic diseases resulting from immune system disruptions. Its portfolio includes ImotopeTM, which targets type 1 diabetes, and it also works on therapeutic vaccines for conditions such as multiple sclerosis and other autoimmune, inflammatory, and infectious diseases. ImCyse's innovative approach involves the creation of specific immune therapies that can selectively destroy harmful immune cells while generating new cytolytic CD4 T-cells, thereby enhancing treatment efficacy and minimizing adverse immunogenic responses.
Lumeon Ltd. is a digital health company specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and headquartered in London, the company offers a cloud-based platform known as the Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. Lumeon's services encompass business analysis, project management, data migration, training, and ongoing support. By focusing on the entire care pathway, Lumeon aids healthcare providers in optimizing clinical and administrative workflows, automating tasks, and achieving measurable healthcare outcomes. The company serves a diverse range of clients, including some of Europe's leading healthcare organizations. Lumeon was previously known as Qinec Ltd. before rebranding in July 2016.
Aelin Therapeutics is a Belgian biotherapeutics company established in 2017 and headquartered in Heverlee. It specializes in developing innovative antibiotics and therapeutics through its proprietary Pept-in technology, which utilizes protein aggregation to achieve functional knockdown of target proteins. This platform is designed to address challenging medical conditions, including infections caused by Methicillin-resistant Staphylococcus aureus (MRSA) and other undruggable targets in humans. The company was founded by VIB in collaboration with partner universities, including KU Leuven, VUB, and UGent, and is backed by extensive preclinical proof-of-concept data. Aelin Therapeutics' approach allows for the rational design of novel biotherapeutics, distinguishing itself from traditional therapeutic modalities by targeting intracellular spaces typically inaccessible to small molecules or antibodies. The technology's versatility extends beyond human applications, demonstrating efficacy against bacteria, cancer cells, fungi, viruses, and even plant cells.
Nouscom is a biotechnology company focused on developing innovative immunotherapy solutions for cancer treatment. Headquartered in Basel, Switzerland, with operations in Rome, Italy, the company specializes in engineered viral vector vaccines. Their platform is designed to express long strings of tumor neoantigens, facilitating the induction of strong antitumor T-cell responses to enhance cancer-specific cellular immunity. The leadership team, including experienced entrepreneurs like Prof. Riccardo Cortese, brings a wealth of expertise from previous successful ventures in the field of oncolytic and genetic vaccines.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.
Rainier Therapeutics is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to inhibit the activity of FGFR3 (fibroblast growth factor receptor 3), which is crucial in the treatment of both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics before rebranding in November 2018. Through its innovative approach, Rainier Therapeutics aims to enhance treatment options for patients suffering from this challenging disease.
Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. Its primary product, IMU-838, is a selective immune modulator currently in Phase 2 clinical trials for ulcerative colitis, relapsing-remitting multiple sclerosis, and Crohn's disease. Additionally, the company is advancing IMU-935, an inverse agonist targeting RORgt, and IMU-856, which aims to restore intestinal barrier function in patients with conditions such as inflammatory bowel disease and irritable bowel syndrome. Immunic Therapeutics is headquartered in New York, New York, and seeks to provide effective treatment options for a range of chronic inflammatory conditions through its innovative drug development initiatives.
Luxendo will manufacture and sell advanced Single Plane Illumination Microscopes (SPIM) originally developed at EMBL by Lars Hufnagel and his team. SPIM is a rapidly emerging technology that combines optical sectioning with multiple-view imaging to observe tissues and living organisms with impressive resolution. Unlike the conventional techniques of widefield and confocal fluorescence microscopy, the light sheet technique illuminates on the region surrounding the focal plane of the detection objective in a twin objective configuration.
Ventaleon is developing inhaled treatments against viral infections. The Company’s lead therapy, is an inhaled LASAG (D,L-lysine acetylsalicylate • glycine), a lysin-salt formulation of well-known acetyl salicylic acid (Aspirin®), suitable as an ingredient for inhalable aerosol, has completed Phase II clinical trials to treat severe influenza. A proof-of-concept study in influenza patients with moderate to severe symptoms demonstrated more rapid symptom decline when administered via inhaled LASAG compared to standard of care. The Company is currently preparing to enter a pivotal clinical trial with inhaled LASAG. Ventaleon was founded as a spin-off from Activaero, a leading specialist in aerosol inhalation therapies and technologies, in 2012
Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.
To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics. Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.
Curetis N.V. is a commercial-stage molecular diagnostics company based in Holzgerlingen, Germany, specializing in solutions for severe infectious diseases. The company develops and manufactures a range of molecular microbiology products aimed at detecting various pathogens, including bacteria and fungi, as well as identifying genetic markers for antimicrobial resistance. Key offerings include the Unyvero L4 Lysator for sample pre-processing, the Unyvero A50 Analyzer, and the Unyvero C8 Cockpit, which serves as a control panel for these devices. Curetis also provides Unyvero Application Cartridges for syndromic infectious disease testing and the ARES AMR Database, which compiles data on antimicrobial resistance genetics. Its tests cover multiple infections, including pneumonia and urinary tract infections. Founded in 2007, Curetis has established strategic partnerships with companies like MGI Tech Co. Ltd. and Qiagen N.V., enhancing its capabilities in the molecular diagnostics market.
Activaero GmbH is a drug delivery company focused on the research, development, manufacture, and marketing of controlled breathing technologies for inhaled therapeutic agents. Based in Gemunden, Germany, with additional locations in Munich and Dublin, Ohio, Activaero offers a range of innovative products, including AKITA, a controlled breathing device equipped with smart card technology, and Watchhaler, designed specifically for children requiring inhaled medication. The company's technologies aim to ensure efficient and safe drug deposition in the lungs, addressing severe respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and idiopathic pulmonary fibrosis. Activaero also provides AKITA² for clinical trial settings and LimiX, a flow limitation valve that regulates flow rates. Additionally, the company offers measurement and diagnostic technologies for laboratory use and contract development services for clinical trials. Its products are marketed through a network of distributors. Founded in 2004, Activaero is dedicated to improving therapy outcomes for patients with lung diseases.
Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.
Affectis Pharmaceuticals is a company focused on developing innovative drugs aimed at treating neurodegenerative and neuroinflammatory diseases. The firm specializes in discovering and advancing therapies for psychiatric and inflammatory disorders, drawing on research related to conditions such as depression and schizophrenia. By leveraging scientific insights, Affectis seeks to address unmet medical needs in these challenging areas of healthcare.
BMEYE B.V. is a Netherlands-based company focused on the research and development of non-invasive cardiovascular monitoring technologies. Established in 2005 and located in Amsterdam, BMEYE specializes in devices that measure blood pressure and cardiac output. Its product lineup includes the Finapres, a continuous finger blood pressure monitor; Portapres, an ambulatory version of the same technology; and the Finometer, a stationary monitor that provides non-invasive brachial pressure measurements. Additionally, BMEYE offers BeatScope, a software tool for analyzing arterial pressure waveforms, and Modelflow, a method for computing aortic flow waveforms. The company also has various devices like Cardiopres and Oxyflow for specific applications in research and clinical settings. BMEYE's products are distributed through a network of distributors and have received approval for sale in the U.S. and Europe, particularly targeting markets such as cardiology and anesthesia.
Pasteuria Bioscience, Inc., founded in 2003 at the University of Florida's Sid Martin Biotechnology Incubator, specializes in developing biological nematicides aimed at controlling nematode pests in agricultural crops. Originating from Entomos, Inc., the company focuses on a proprietary manufacturing method that utilizes traditional fermentation techniques to produce various strains of Pasteuria. Having successfully raised over $6 million in venture funding, Pasteuria Bioscience has advanced its technology to commercial-scale production and achieved EPA registration for its inaugural product, designed to combat sting nematodes in professional turf. This product is expected to launch following comprehensive field trials and ongoing commercial development efforts. The company remains committed to expanding its product pipeline and enhancing its intellectual property through rigorous laboratory research.
Attune Foods, Inc. is a producer of organic snacks, headquartered in San Francisco, California, with additional operations in Eugene, Oregon. Established in 2006, the company specializes in probiotic wellness bars available in a variety of flavors, including dark chocolate, chocolate crisp, and mint chocolate, among others. In addition to these bars, Attune Foods offers a range of products such as granolas featuring chocolate or yogurt chips, muesli, cereal products, and graham crackers. The company's focus is on providing customized healthy food options to support consumer wellness.
Efficas Medical Foods & Nutrition, LLC is a health-science and technology company focused on researching, developing, and commercializing products aimed at the nutritional management of the immune system for both humans and pets. The company offers Efficas Care, a berry-flavored non-prescription medical food designed to help manage asthma and associated allergies. Established in 2010 and based in Fullerton, California, Efficas is committed to providing effective nutritional solutions to enhance health and well-being.
KuDOS Pharmaceuticals Ltd discovers and develops drugs based upon the science of DNA damage sensing, signaling, and repair to address medical needs in cancer treatment.
Hybrigenics Pharma is a bio-pharmaceutical company with a focus on research and development of new targets and therapies against cancer.Hybrigenics Pharma has stopped the development of inecalcitol, a vitamin D receptor agonist.Hybrigenics Pharma's research program investigates the action of enzymes called Deubiquitinating Enzymes (DUBs) in the recycling of onco-proteins and the potential activity of proprietary patented DUB inhibitors against various cancer indications.